Back in 2008, the Nasdaq Biotech Index outperformed all major sectors of the SP500 with a negative 12% return. That was a year when investors in large biotechs (the index’s bias) benefited from weak market correlation with the overall market. Every sector went down in 2008, some over 50%, creating…